Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies

Abstract

Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors, particularly osimertinib. Although recent clinical trials have established osimertinib as effective treatment across many stages of EGFR-mutant NSCLC, the inevitable emergence of acquired resistance poses a major therapeutic challenge despite the substantial clinical benefit. Understanding the mechanisms of osimertinib acquired resistance is urgently needed to identify effective strategies to overcome it. Resistance to osimertinib including on-target mechanisms such as novel EGFR secondary mutation, off-target mechanisms such as hepatocyte growth factor receptor or human epidermal growth factor receptor 2 amplification, mutations in downstream signaling molecules, and oncogenic fusions, and the Histological transformations (such as epithelial-mesenchymal transition, squamous cell carcinoma, or small cell lung cancer) have been well described. This review summarizes the mechanisms and clinical significance of osimertinib-acquired resistance in recent years, as well as new clinical treatments. It is expected to provide valuable insights and potential new strategies for the clinical treatment of EGFR-mutated NSCLC patients with osimertinib resistance.

Keywords

NSCLC / osimertinib resistance / molecular mechanisms / clinical therapeutic strategies

References

[1] Han B,Zeng H.Cancer incidence and mortality in China, 2022.J Natl Cancer Cent2024;4:47-53 PMCID:PMC11256708

[2] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[3] Riely GJ,Ettinger DS.Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2024;22:249-74

[4] Riely GJ,Miller VA.Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Clin Cancer Res2006;12:7232-41

[5] Castellanos E,Horn L.Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer.J Thorac Oncol2017;12:612-23

[6] Cote ML,Edwards DJ.Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.J Thorac Oncol2011;6:627-30 PMCID:PMC3057407

[7] Reinersman JM,Riely GJ.Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.J Thorac Oncol2011;6:28-31 PMCID:PMC3337520

[8] O’Kane GM,Feld R.Uncommon EGFR mutations in advanced non-small cell lung cancer.Lung Cancer2017;109:137-44

[9] Meador CB,Piotrowska Z.Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates.Cancer Discov2021;11:2145-57 PMCID:PMC8673432

[10] Borgeaud M,Bar J.Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: navigating early to advanced disease management.CA Cancer J Clin2025;75:387-409 PMCID:PMC12432819

[11] Mok TS, Wu Y-L, Ahn M-J, et al; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629-40. PMCID:PMC6762027

[12] Papadimitrakopoulou VA,Han JY.Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.Ann Oncol2020;31:1536-44

[13] Reungwetwattana T,Cho BC.CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer.J Clin Oncol2018;36:3290-7

[14] Park S,Jung HA.Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM).J Clin Oncol2024;42:2747-56 PMCID:PMC11315406

[15] Ma J,Han C.Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.Ther Adv Med Oncol2024;16:17588359241289648 PMCID:PMC11492187

[16] Ramalingam SS, Vansteenkiste J, Planchard D, et al; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.

[17] Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25.

[18] Passaro A,Blackhall F.ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.Ann Oncol2022;33:466-87

[19] Chen S,Sun B.Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC.Cancer Biol Med2025;22:191-6 PMCID:PMC11976710

[20] Herbst RS,John T.Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial.J Clin Oncol2023;41:1830-40 PMCID:PMC10082285

[21] Sidaway P.Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC.Nat Rev Clin Oncol2024;21:566

[22] Lu S,Reungwetwattana T.Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.Ann Oncol2024;35:1116-25

[23] Wu F,Neal JW.Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.Transl Lung Cancer Res2024;13:2853-5 PMCID:PMC11535829

[24] Lv C,Wu N.Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial.Lung Cancer2023;178:151-6

[25] Lee JM,Toloza E.Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives.J Thorac Oncol2023;18:1458-77 PMCID:PMC11040203

[26] Blakely CM,Gubens MA.Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study.J Clin Oncol2024;42:3105-14 PMCID:PMC11379363

[27] He J, Tsuboi M, Weder W, et al; NeoADAURA Investigators. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2025;43:2875-87.

[28] Lee JB,Shim HS.Neoadjuvant and adjuvant osimertinib in stage IA to IIIA, EGFR-mutant NSCLC (NORA).J Thorac Oncol2025;20:641-50

[29] Ramalingam SS.Neoadjuvant osimertinib: a step ahead or just a step?.J Clin Oncol2025;43:2847-50

[30] Planchard D, Jänne PA, Cheng Y, et al; FLAURA2 Investigators. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-48.

[31] Passaro A, Wang J, Wang Y, et al; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35:77-90.

[32] Du X,An Q,Cao X.Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.Innovation2021;2:100103 PMCID:PMC8454558

[33] Leonetti A,Minari R,Giovannetti E.Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.Br J Cancer2019;121:725-37 PMCID:PMC6889286

[34] Zheng Q,Qi W.NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China.Lung Cancer2024;194:107897

[35] Vendrell JA,Aussel A,Serre I.EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.Transl Lung Cancer Res2021;10:4084-94 PMCID:PMC8674606

[36] Cross DA,Ghiorghiu S.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Cancer Discov2014;4:1046-61 PMCID:PMC4315625

[37] Remon J.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Future Oncol2015;11:3069-81

[38] Nagano T,Nishimura Y.Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy.Cells2018;7:212 PMCID:PMC6262543

[39] Chmielecki J,Wu YL.Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.Nat Commun2023;14:1071 PMCID:PMC9971022

[40] Piotrowska Z, Ahn M, Pang Y, et al. LBA53 ELIOS: a multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib. Ann Oncol. 2022;33:S1420-1. Available from: https://www.annalsofoncology.org/article/S0923-7534(22)03933-3/fulltext. [Last accessed on 5 Nov 2025].

[41] Oxnard GR,Mileham KF.Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib.JAMA Oncol2018;4:1527-34 PMCID:PMC6240476

[42] Li Y,Wang J.Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Cell Commun Signal2023;21:71 PMCID:PMC10088170

[43] Choudhury NJ,Sui JSY.Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.J Thorac Oncol2023;18:463-75 PMCID:PMC10249779

[44] Ramalingam S, Cheng Y, Zhou C, et al. LBA50 - mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:mdy424.063. Available from: https://academic.oup.com/annonc/article/29/suppl_8/mdy424.063/5142018. [Last accessed on 5 Nov 2025].

[45] Bertoli E,Del Conte A.Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it?.Int J Mol Sci2022;23:6936 PMCID:PMC9266773

[46] Chmielecki J,Cheng Y.Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.Nat Commun2023;14:1070 PMCID:PMC9971254

[47] Brown BP,Westover D.On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation.Clin Cancer Res2019;25:3341-51 PMCID:PMC6548651

[48] Jia Y,Park E.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.Nature2016;534:129-32 PMCID:PMC4929832

[49] To C,Chen T.Single and dual targeting of mutant EGFR with an allosteric inhibitor.Cancer Discov2019;9:926-43 PMCID:PMC6664433

[50] Beyett TS,Heppner DE.Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.Nat Commun2022;13:2530 PMCID:PMC9085736

[51] Eno MS,Campbell JE.Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer.J Med Chem2022;65:9662-77 PMCID:PMC9340769

[52] Lim SM,Lee EJ.BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.Ther Adv Med Oncol2024;16:17588359241280689 PMCID:PMC11497503

[53] BDTX-1535 goes after osimertinib resistance. Cancer Discov. 2021;11:2952-3.

[54] Yu H,Henry JT.Abstract C022: phase 1 study of BDTX-1535, an oral 4^th generation inhibitor, in patients with non-small cell lung cancer and glioblastoma: preliminary dose escalation results.Mol Cancer Ther2023;22:C022

[55] Gawli CS,Patel HM.A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Bioorg Med Chem2025;123:118146

[56] Zhou R,Zhang W,Li X.Combination of osimertinib and anlotinib may overcome the resistance mediated by in cis EGFR T790M-C797S in NSCLC: a case report.Onco Targets Ther2021;14:2847-51 PMCID:PMC8093742

[57] Park W,Xie CL.Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.Exp Mol Med2024;56:1137-49 PMCID:PMC11148081

[58] Lee SH,Lee E.Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion.NPJ Precis Oncol2024;8:111 PMCID:PMC11109121

[59] Michels BE,Streibl BI.Pooled in vitro and in vivo CRISPR-Cas9 screening identifies tumor suppressors in human colon organoids.Cell Stem Cell2020;26:782-92.e7

[60] Schuster B,Kashaf SS.Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids.Nat Commun2020;11:5271 PMCID:PMC7573629

[61] Kheiri S,Cruickshank J.Microfluidic platform for generating and releasing patient-derived cancer organoids with diverse shapes: insight into shape-dependent tumor growth.Adv Mater2024;36:e2410547

[62] Liang H.MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis.Onco Targets Ther2020;13:2491-510 PMCID:PMC7104217

[63] Lei H,Wei J.EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma.Transl Cancer Res2021;10:233-40 PMCID:PMC8797278

[64] Mehlman C,Monnet I.COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.Oncologist2025;30:oyae312 PMCID:PMC12395140

[65] Engelman JA,Mitsudomi T.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science2007;316:1039-43

[66] Urbanska EM,Koffeldt PR.Real-world data on combined EGFR-TKI and crizotinib treatment for acquired and de novo MET amplification in patients with metastatic EGFR-Mutated NSCLC.Int J Mol Sci2023;24:13077 PMCID:PMC10487649

[67] Hartmaier RJ,Ahn MJ.Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON.Cancer Discov2023;13:98-113 PMCID:PMC9827108

[68] Wu YL, Guarneri V, Voon PJ, et al; INSIGHT 2 investigators. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25:989-1002.

[69] de Marinis F,Bonanno L.Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.Ann Oncol2025;36:920-33

[70] Takamori S,Yamaguchi M.Case report: success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.Front Oncol2022;12:965741 PMCID:PMC9608750

[71] Suzawa K,Schoenfeld AJ.Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer.JCO Precis Oncol2019;3:1-8 PMCID:PMC6541452

[72] Elghawy O,Reed-Guy L.Brief report: osimertinib plus capmatinib for patients with MET-altered EGFR-mutant NSCLC following progression on front line therapy.Clin Lung Cancer2025;26:158-63.e2

[73] Moores SL,Bushey BS.A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors.Cancer Res2016;76:3942-53

[74] Besse B,Wang Y.Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A.J Thorac Oncol2025;20:651-64

[75] Horinouchi H,Camidge DR.Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.Ann Oncol2025;36:583-91

[76] Remon J.Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer?.Ann Oncol2025;36:484-7

[77] Guo R,Chang J,Arcila M.MET-dependent solid tumours - molecular diagnosis and targeted therapy.Nat Rev Clin Oncol2020;17:569-87 PMCID:PMC7478851

[78] Takezawa K,Arcila ME.HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR^T790M mutation.Cancer Discov2012;2:922-33 PMCID:PMC3473100

[79] Namba K,Takahashi Y.Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells.Mol Cancer Res2019;17:499-507

[80] Jebbink M,Monkhorst K.Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC.JTO Clin Res Rep2023;4:100481 PMCID:PMC10074240

[81] Hirata HM,Chen KY.Fam-trastuzumab-deruxtecan and osimertinib combination to target HER2 driven resistance in a patient with NSCLC after osimertinib progression: case report.JTO Clin Res Rep2025;6:100787 PMCID:PMC11907440

[82] Park S,Han JY.Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04).J Clin Oncol2024;42:1241-51 PMCID:PMC12333514

[83] Lei T,Zhang N.Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.Pharmacol Res2023;188:106668

[84] Simoni-Nieves A,Giri S.A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.Cell Rep Med2024;5:101703 PMCID:PMC11528239

[85] Dou Y,Han R.Multieffect specific nanovesicles for homing resistant tumors and overcoming osimertinib-acquired resistance in NSCLC.Adv Healthc Mater2025;14:e2404087

[86] Kole E,Singh R.Recent developments in tyrosine kinase inhibitor-based nanotherapeutics for EGFR-resistant non-small cell lung cancer.Curr Drug Deliv2025;22:249-60

[87] Nakamura R,Tokuda S.Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.Cancer Lett2024;598:217124

[88] Weng CD,Jin S.Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAFV600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients.Transl Lung Cancer Res2024;13:2538-48 PMCID:PMC11535828

[89] Wang Y,Zhou LQ.NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway.Am J Cancer Res2024;14:5680-96 PMCID:PMC11711526

[90] Xu X,Gong Q.PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.Cancer Chemother Pharmacol2024;94:209-21

[91] Haratake N,Morimoto Y.MUC1-C is a common driver of acquired osimertinib resistance in NSCLC.J Thorac Oncol2024;19:434-50 PMCID:PMC10939926

[92] Dayanc B,Gulfirat NE.Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.Cell Death Dis2025;16:414 PMCID:PMC12104440

[93] Shintani T,Toyozumi Y.MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma.Sci Rep2024;14:24429 PMCID:PMC11489462

[94] Miao Z,He J.Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop.Drug Resist Updat2025;83:101245

[95] Xu L,Xing L.LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis.Front Pharmacol2025;16:1592846 PMCID:PMC12043721

[96] Li Y,Huang Y.CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.Cancer Genet2024;284-285:34-42

[97] Hung CH,Yao CD.Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer.Nat Commun2024;15:7885 PMCID:PMC11385228

[98] Fan S,Zhang C.METTL14-mediated bim mRNA m6A modification augments osimertinib sensitivity in EGFR-mutant NSCLC cells.Mol Cancer Res2024;22:1051-63

[99] Song H,Jang SJ,Song JS.Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.Ann Diagn Pathol2025;77:152478

[100] Marcoux N,O’Kane G.EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes.J Clin Oncol2019;37:278-85 PMCID:PMC7001776

[101] Banerjee A,Halder D.Molecular landscape and therapeutic strategies of lung cancer lineage plasticity.J Thorac Oncol2025;20:1582-93

[102] Ding J,Gu H,Song Y.Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.Front Oncol2023;13:1153131 PMCID:PMC10288518

[103] Zhao S,Yang W.The next generation of immunotherapies for lung cancers.Nat Rev Clin Oncol2025;22:592-616

[104] Zhou J,Li Z.PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Cell Death Dis2024;15:644 PMCID:PMC11372188

[105] Li H,Zheng X.RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.Oncogene2025;44:307-21 PMCID:PMC11779629

[106] Sui Y,Pan R.AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under osimertinib pressure.Cell Death Dis2025;16:298 PMCID:PMC12000569

[107] Shinozaki T,Hamamoto J.Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.Nat Commun2025;16:4369 PMCID:PMC12066730

[108] Fu C,Zhu W.Case report: durable complete response to antigen-specific cytotoxic T lymphocyte therapy in advanced EGFR-TKI resistant lung adenocarcinoma: a case of adoptive cellular immunotherapy overcoming acquired targeted resistance.Front Immunol2025;16:1637165 PMCID:PMC12433949

[109] Sun D,Feng F.A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome osimertinib resistance of ARID1A-deficient lung adenocarcinoma.Exp Hematol Oncol2025;14:3 PMCID:PMC11705878

[110] Huang Y,Wen C,Zhou H.Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis.MedComm2024;5:e653 PMCID:PMC11260172

[111] Zhang C,Xu H.Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.Oncogene2025;44:1400-14 PMCID:PMC12052591

[112] Li YS,Yin K.Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.Cell Rep2024;43:114613

[113] Martin MJ,Calero F.Abstract LB458: osimertinib treatment drives expression of TROP2, and combination treatment with datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer.Cancer Res2025;85:LB458

[114] Lu S,Lisberg A.TROPION-Lung14: a phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).JCO2025;43:TPS8647

[115] Patil T,Watson A.The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.Lung Cancer2025;199:108040 PMCID:PMC11787869

[116] Hong S,Cheng Y.First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.Nat Med2025;31:3654-61

[117] Zhang T,Gao J.Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.Signal Transduct Target Ther2024;9:216 PMCID:PMC11324870

[118] Han R,Hu C.Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.Acta Pharmacol Sin2024;45:1264-75 PMCID:PMC11130302

[119] Parisi C,Gazzah A.TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).Cancer Treat Rev2023;118:102572

[120] Lu S, Kato T, Dong X, et al; LAURA Trial Investigators. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391:585-97.

[121] Zhou J,Lv D.73P: Real-world post-progression analysis of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study).J Thorac Oncol2025;20:S55

[122] Zhou J,Lv D.665P real-world effectiveness and safety of first-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: a prospective, multi-center, real-world study in China (FLOURISH Study).Ann Oncol2024;35:S1653-4

[123] Fu M,Zhang L.Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade.Cancer Cell2024;42:1882-97.e7

[124] Cao L,Yu T.Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.Biochem Pharmacol2024;224:116207

[125] Grazini U,Ireland L.Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA/PTEN alterations.Clin Cancer Res2024;30:4143-54